Strong medicine for weak drug patents
Revocation of Pfizer, Roche patents for lacking inventive step signals healthy trend
Biodiversity—India’s other scandal
CAG slams the national biodiversity authority for allowing questionable patents
Free trade will bind India
Crazy for GI? Think again
The protection of Geographical Indication is not a guarantee that the artisan or producer will benefit; traders can corner the premium
A rather ridiculous gap
Clothing giant Gap’s trademark infringement notice to an NGO selling products made from recycled waste is a curious case
India’s 3 D Message
The Supreme Court judgment in the Novartis case clearly upholds India’s patent laws, not weakens the patent regime
The fine line for judges
Judges have recused themselves in a number of cases but there are no clear guidelines on what constitutes conflict of interest
Legislation for a few
Benefits of the Act that encourages conservation of plants reach few farmers
NCD battle starts now
The UN agreement on non-communicable diseases will get snagged on the issue of intellectual property rights for drugs
Obama takes first dip
The US becomes the first to join a global patents pool to make AIDS drugs cheaper but health workers are sceptical of the initiative
Access, yes. Sharing, no
The access and benefit-sharing protocol on biodiversity may do little to deter multinationals from grabbing the planet’s resources
Yale guide to fighting drug patent barriers
How human rights can be used to challenge oppressive intellectual property laws
European Parliament rejects Anti-Counterfeiting Trade Agreement
Act makes it possible to seize and destroy even legitimately produced generic drugs exported from India to poor countries
Act of omission
Public institutions do not seek permission from the biodiversity authority before genetically manipulating crops
Rajasthan opens farm gates
State ties up with Monsanto, other biotech giants to restructure agriculture
Cipla's audacious move
Why generics maker Cipla has asked government to revoke Novartis patent on respiratory ailment drug
US keeps India out of Priority Foreign Country list of 'worst IP offenders'
US Trade Representative’s Special 301 Report keeps up pressure on India to fall in line with US’ interests
The natco-pfizer test
Natco’s demand for a voluntary licence from Pfizer will establish how well the compulsory licence process works in India
It’s still open season for bio-piracy
Rich nations block accord on benefit-sharing rules for the world’s genetic resources
Whose germplasm is it?
NBA struggles to frame case against Mahyco in first biopiracy case
Gunning for green tech
US continues to target India over its intellectual property regime, especially in pharma, green tech sectors
Choking access to drugs
Drug prices are likely to increase as rich countries and their pharma companies squeeze Indian generics out of the market. How can India’s …
Patent hypocrisies of US
American business lobbies are spreading falsehoods about India’s patent policies—and glossing over their double standards
No climate for cleantech
Most of the clean energy innovations are with just six rich countries and hardly any technology is coming to developing nations
A lethal secrecy in trade deals
Why do democratic governments hide trade negotiations that have dire consequences for public services?